Lung Cancer Clinical Trials in New York, NY

Lung Cancer Clinical Trials in New York, NY

View the best 10 lung cancer medical studies in New York, New York. Access promising new therapies by applying to a New York-based Lung Cancer clinical trial.

Trials in New York, New York

Here are the top 10 medical studies for lung cancer in New York, New York

Image of Massachusetts General Hospital in Boston, United States.

JDQ443

KRAS G12C Inhibitor

Recruiting1 awardPhase 1 & 2
This trial tests JDQ443, a new drug, combined with other treatments for patients with advanced cancers having the KRAS G12C mutation. The drug aims to stop cancer growth by targeting a specific genetic fault.
Image of Alaska Oncology and Hematology, LLC. in Anchorage, United States.

Carboplatin +3 More

Alkylating agents

Recruiting1 awardPhase 2
This trial is testing a new combination therapy for advanced or metastatic non-small-cell lung cancer (NSCLC) that has not responded to other treatments. The primary objectives are to assess the objective response rate (ORR) and to determine the recommended Phase 2 dose (RP2D) of the new therapy.
Image of Roswell Park Cancer Institute in Buffalo, United States.

Stereotactic Body Radiation Therapy

Recruiting1 awardPhase 1
This trial is testing the side effects of single fraction stereotactic body radiation therapy after surgery in treating patients with non-small cell lung cancer.
Image of Research Site - Orange City in Orange City, United States.

HLX10

Monoclonal Antibodies

Verified
Recruiting3 awardsPhase 3
This trial is testing two different treatment combinations for patients with extensive-stage small cell lung cancer who have not received any prior treatment. One group will receive a new drug called Serplulimab along with standard chemotherapy, while the other group will receive an existing drug called Atezolizumab with the same chemotherapy. Both immunotherapy drugs aim to help the immune system fight cancer, and the chemotherapy drugs work by killing cancer cells. Atezolizumab has been shown to improve survival in small-cell lung cancer when combined with chemotherapy, changing the standard first-line therapy.
Image of City of Hope in Duarte, United States.

SRF388

Monoclonal Antibodies

Recruiting1 awardPhase 1
This trial tests CHS-388, a protein that blocks IL-27, in patients with severe cancers like kidney, liver, and lung cancer. The goal is to see if it helps the immune system fight cancer better.
Image of USC Norris Comprehensive Cancer Center in Los Angeles, United States.

PC14586 +1 More

Small Molecule

Recruiting1 awardPhase 1 & 2
This trial is testing a new oral drug, PC14586 (rezatapopt), alone and with pembrolizumab, in patients with advanced cancers that have a specific genetic mutation. The drug aims to fix a mutated protein to help control cancer growth. The study will determine the best dose and evaluate the drug's safety and effectiveness.
Image of Reading Hospital in West Reading, United States.

Carboplatin +6 More

Chemotherapy

Recruiting2 awardsPhase 3
This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.
Image of Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0122) in Omaha, United States.

Carboplatin +7 More

Platinum-based Chemotherapy Agent

Recruiting1 awardPhase 2
This trial is testing new drugs combined with existing treatments and chemotherapy to see if they can better treat patients with severe, widespread lung cancer by boosting the immune system and enhancing chemotherapy effects.
Image of University of California Davis Medical Center in Sacramento, United States.

Frequency: Every 6 Months

Recruiting1 award6 criteria
This trial will help determine if a more frequent or less frequent surveillance strategy for extremity STS patients after surgery impacts patient survival rates.
Image of Alabama Oncology Bruno Cancer Center ( Site 0001) in Birmingham, United States.

Carboplatin +3 More

Chemotherapy

Recruiting1 awardPhase 3
This trial will compare two treatments for people with squamous non-small cell lung cancer. One treatment will be pembrolizumab plus maintenance olaparib, and the other will be pembrolizumab plus maintenance olaparib placebo. The study's two primary hypotheses are that pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance olaparib placebo with respect to progression-free survival and overall survival.

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.